|
Post by wyattdog on Jun 19, 2019 9:22:30 GMT -5
from sunnyholiday on st JMP presentation take-away: Brasil hyped approval of Afrezza - first order of BIOMM received - DPI/Technosphere platform approval by FDA - no competition in sight next 5-10 years - develope molecules to phase I and licence out - unknown UTHR molecule progresses - trial to standarize Afrezza use was 95% successful - Kids study Phase III starting soon - 2000 consistent prescribers - target of sales force: 4-5K endos plus primary care - just signed a 5-year-deal with Kaisers, which is a "big thing" according the last questioner. Enough cash till 2nd half 2020. Didn't want to sell stock to Deerfield at these prices. Yes, things take more time than anyone would have thought and could wish for. But that's part of the business, it seems. Quite content and Correction: Cash till 2nd quarter (not half) of 2020. Listen to it at 21:18.
|
|
|
Post by goyocafe on Jun 19, 2019 9:30:13 GMT -5
“2000 consistent prescribers” I find this number hard to believe. How many patients does an ENDO see in a week regarding diabetes? And of those how many get a prescription for insulin? And of those how often do they consider Afrezza as the insulin of choice? Based on NRx numbers, that would be maybe 1 patient every three weeks per consistent prescriber. Consistent is the inoperative word imo.
|
|
|
Post by scottmnkd on Jun 19, 2019 10:24:05 GMT -5
Same sh t different presentation. yawwwn Hopefully Mike's "excitement" will someday turn into profitable dollars. For me, the recent positive change is the focused sales in targeted regions (something they should have started with IMHO).
|
|
|
Post by awesomo on Jun 19, 2019 11:28:12 GMT -5
Didn't want to sell stock to Deerfield at these prices. Well, down 4% after his presentation so I guess he wanted to give them a bigger discount?
|
|
|
Post by cedafuntennis on Jun 19, 2019 12:22:25 GMT -5
PATIENT RETENTION is key. 2000 prescribers or whatever means nothing without increasing retention percentage drastically.
That is MY take on it... Sorry to plagiarize Sir, just couldn't resist...
|
|
|
Post by mytakeonit on Jun 19, 2019 13:06:49 GMT -5
Retention? Seems that if we have 2000 consistent prescribers then we do have retention. It also seems that the prescriber numbers are growing from where we were at the beginning of the year. Were we at 40 prescribers then? Ha! Only joking. I think ... Anyway, we are getting there. The only thing I hope is that some awesome guy can get the share prices down to where my buy orders are. I'm not even going to play my Brasil card yet. But, that's mytakeonit
|
|
|
Post by wyattdog on Jun 19, 2019 14:05:45 GMT -5
mike's quote about Brazil " Biomm made the front page of 2 national newspapers, over 60 appearances in local media, doctors putting out their own blogs and news media picking up on live tv. you ask yourselves what's the difference between the u.s. marketplace and Brazil. alot of it goes back to the fact they have not had any major innovations in diabetes in 90 years. when you think about the u.s. everyone wants to talk about pumps time in range and algorithms and that's the cure but when you go to the rest of the world there is not alot of pump penetration. usually less than 10% of the market. so for those patients they don't have cgm they don't have pumps they just have injectable insulin and afrezza is really the first alternative they will have in a long time." '
|
|
|
Post by mytakeonit on Jun 19, 2019 14:17:27 GMT -5
Hopefully the first container load is on the water already. Let's get that Danbury plant cranking !!!
But, that's mytakeonit
|
|
|
Post by rtmd on Jun 19, 2019 15:31:56 GMT -5
mike's quote about Brazil " Biomm made the front page of 2 national newspapers, over 60 appearances in local media, doctors putting out their own blogs and news media picking up on live tv. you ask yourselves what's the difference between the u.s. marketplace and Brazil. alot of it goes back to the fact they have not had any major innovations in diabetes in 90 years. when you think about the u.s. everyone wants to talk about pumps time in range and algorithms and that's the cure but when you go to the rest of the world there is not alot of pump penetration. usually less than 10% of the market. so for those patients they don't have cgm they don't have pumps they just have injectable insulin and afrezza is really the first alternative they will have in a long time." ' Any info on when the pricing decision will be made in Brazil?
|
|
|
Post by goyocafe on Jun 19, 2019 16:14:17 GMT -5
mike's quote about Brazil " Biomm made the front page of 2 national newspapers, over 60 appearances in local media, doctors putting out their own blogs and news media picking up on live tv. you ask yourselves what's the difference between the u.s. marketplace and Brazil. alot of it goes back to the fact they have not had any major innovations in diabetes in 90 years. when you think about the u.s. everyone wants to talk about pumps time in range and algorithms and that's the cure but when you go to the rest of the world there is not alot of pump penetration. usually less than 10% of the market. so for those patients they don't have cgm they don't have pumps they just have injectable insulin and afrezza is really the first alternative they will have in a long time." ' Any info on when the pricing decision will be made in Brazil? That’s a great question? How did they get their first order without pricing being resolved?
|
|
|
Post by mnholdem on Jun 19, 2019 16:28:42 GMT -5
mike's quote about Brazil " Biomm made the front page of 2 national newspapers, over 60 appearances in local media, doctors putting out their own blogs and news media picking up on live tv. you ask yourselves what's the difference between the u.s. marketplace and Brazil. alot of it goes back to the fact they have not had any major innovations in diabetes in 90 years. when you think about the u.s. everyone wants to talk about pumps time in range and algorithms and that's the cure but when you go to the rest of the world there is not alot of pump penetration. usually less than 10% of the market. so for those patients they don't have cgm they don't have pumps they just have injectable insulin and afrezza is really the first alternative they will have in a long time." ' Perhaps the difference isn’t because of the country but because of the companies. Biomm obviously understands the value of reaching out to the media. MannKind does not so their efforts to get the media excited have been minimal and narrow. Radio interview at an Alma Mater, logo on a race car, rapper, “Reversed” show (which didn’t even spotlight Afrezza) ...all U.S. communication channels that would totally miss 99% of physicians and likely 90% of PWD’s.
|
|
|
Post by mnkdfann on Jun 19, 2019 17:36:27 GMT -5
Any info on when the pricing decision will be made in Brazil? That’s a great question? How did they get their first order without pricing being resolved? Yes, "first order of BIOMM received" is disturbingly vague. For all we know, it could be a few dozen sample packs to hand out to local endos / docs. Realistically, how big an order would BIOMM place without first having some assurance the price will be something they can work with.
|
|
|
Post by mytakeonit on Jun 19, 2019 20:20:52 GMT -5
Realistically it'll be a container load. Going that far, it's more economical to do a container load.
But, that's mytakeonit
|
|
|
Post by kite on Jun 19, 2019 20:37:18 GMT -5
Biomm has already placed an order for Afrezza... and has been receiving a lot of media attention in Brazil Has Mannkind announced anything to that effect? MC mentioned it in todays Conference Call at 03:58 This will launch in the second half of 2019!!
|
|